Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Wolfe Research analyst Jacob Lacks upgrades RXO (NYSE:RXO) from Underperform to Peer Perform.
Morgan Stanley analyst Ravi Shanker upgrades RXO (NYSE:RXO) from Equal-Weight to Overweight and announces $19 price target.
UBS analyst Thomas Wadewitz maintains RXO (NYSE:RXO) with a Neutral and lowers the price target from $17 to $15.
Truist Securities analyst Lucas Servera maintains RXO (NYSE:RXO) with a Buy and lowers the price target from $22 to $20.
Barclays analyst Brandon Oglenski maintains RXO (NYSE:RXO) with a Overweight and lowers the price target from $17 to $15.
Susquehanna analyst Bascome Majors maintains RXO (NYSE:RXO) with a Negative and lowers the price target from $11 to $10.
RXO (NYSE:RXO) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.04 by 72.22 per...
